From our Center
Articles, News, Press Releases
Congratulations to Dr. Vinicio de Jesus Perez on receiving $3.5M NIH Grant addressing Pulmonary Vascular Disease
Stanford Clinical Center for the NIH Lung Transplant Consortium Awarded NIH Lung Transplant Consortium Center Grant (U01)
Welcome 2022-2023 Fellows
Lea Steffes, MD: Pediatric eBay Fellow in Pulmonary Vascular Disease
Congratulations, Dr. Marsden!
Dr. Alison Marsden, Professor and Wall Center scholar in the departments of Pediatrics, Bioengineering, and, by courtesy, Mechanical Engineering, was recently appointed Nola Leishman Professors in Cardiovascular Diseases. Her work focuses on the development of numerical methods for cardiovascular blood flow simulation, medical device design, application of optimization to large-scale fluid mechanics simulations, and application of engineering tools to impact patient care in cardiovascular surgery and congenital heart disease.
Credit: The Pulmonary Vascular Research Institute (PVRI)
Wall Center Faculty Attend the 15th PVRI Annual World Congress on PVD in Athens, Greece
Congratulations 2022 Graduating PH fellows
Congratulations and a huge thank you to our 2022 graduating PH fellows: Noura Alturaif, MBBS, Raquel Lyn, MD, and Ege Ozdemir, MD. We are so proud of the physicians you are and have become!
The Wall Center Participates at the Stanford Wellness Fair
After a 2 year haitus, the Wall Center participated in-person at the 2022 Wellness Fair on May 24, 2022, held at Koret Plaza. The Wellness Fair is a celebration of wellness and healthy lifestyle choices. Wall Center staff were on-hand to answer questions about the center, pulmonary hypertension and to promote the 22nd Race Against PH.
Congratulations, Dr. Vinicio de Jesus Perez!
Human Cell Atlas Cover Feature on Science Magazine
Dr. Krasnow signs Registry of Membership at the National Academy of Sciences
Mark Krasnow, MD, PhD, a 2019 National Academy of Sciences (NAS) inductee/now member, signed the Registry of Membership at the National Academy of Sciences 159th Annual Meeting. The ceremony was elayed due to pandemic. Dr. Krasnow, serves as the Executive Director, Wall Center for Pulmonary Vascular Disease.
"NAS membership is a widely accepted mark of excellence in science and is considered one of the highest honors that a scientist can receive. Members are elected to the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research."
2022 Years of Service Awards
The Wall Center’s success is directly attributed to the support and contributions of its team members. This year we recognize and congratulate the following people for their service:
- Stephen Chang, MD, PhD
- Aileen Lin, RN, MSN, FNP-BC
- Avin Veerakumar, MD & PhD Candidate
- Jordan Sloan, PA-C, MMS (2021)
- Aiqin Cao, PhD
- Yon Sung, MD, FCCP
- Francois Haddad, MD
- Michelle Ogawa, RN, MSN, PNP
Dr. Vinicio de Jesus Perez gives the 2022 Charles Hales honorary lecture at Massachusetts General Hospital
Dr. Vinicio de Jesus Perez, Associate Professor, Division of Pulmonary, Allergy and Critical Care Medicine recently gave a lecture about the "Role of Dysfucntional Angiogenesis in Pulmonary Hypertension: Implications for Novel Therapeutics" at the Massachusetts General Hospital Ether Dome for the annual Dr. Charles Hales Memorial Lecture.
Congratulations to Dr. Vinicio de Jesus Perez and his team
The Wall Center is pleased to congratulate Dr. Vinicio de Jesus Perez, Associate Professor, Division of Pulmonary, Allergy and Critical Care Medicine and his team for receiving a $3M NIH R01 grant evaluating the pathogenesis of pulmonary arterial hypertension (PAH). In their original R01, his team confirmed a key role for the Wnt7a/ROR2 signaling pathway in lung angiogenesis and how the loss of this mechanism is a feature of PAH vascular pathology.
The renewal grant will focus on elucidating the transcriptional and epigenetic mechanisms governing the behavior of diseased endothelial cells with implications for how the right ventricle adapts in this lethal condition.
Congratulations to Dr. Roham Zamanian and Dr. Kristina Kudelko
The Wall Center is pleased to announce the Appointment of Dr. Roham Zamanian as Associate Director and of Dr. Kristina Kudelko to the Steering Committee. We are incredibly grateful to all those who serve on our committees and lead the Wall Center’s mission and vision.
To eradicate pulmonary vascular disease by discovering fundamental causes, developing innovative therapies, disseminating crucial knowledge, and delivering transformative care.
To transform the way pulmonary vascular disease is understood and treated, both locally and globally.
Stanford (Pulmonology) Ranked #7 in Newsweek's World's Best Specialized Hospitals 2022
Congratulations to the Stanford Chest Clinic (Pulmonology), including Wall Center faculty Mark Nicolls, MD, Professor, Roham Zamanian, MD, Associate Professor and Director of the Adult Pulmonary Hypertension Program, Vinicio de Jesus Perez, MD, Associate Professor, Edda Spiekerkoetter, MD, Associate Professor, Kristina Kudelko, MD, Clinical Associate Professor, Fellowship/Educational Director, Yon Sung, MD, FCCP, Clinical Assistant Professor, and Andrew Sweatt, MD, Clinical Assistant Professor, on ranking #7 in the World's Best Specialized Hospitals 2022-Pulmonology! We applaud your dedication to offer the highest level of care.
Stanford Adult PH Program Receives Reaccreditation as a Center of Comprehensive Care
Congratulations to the Stanford Adult PH Program, on receiving the Pulmonary Hypertension Association (PHA) reaccreditation as a Center of Comprehensive Care, led by Roham Zamanian, MD, Associate Professor in the Division of Pulmonary, Allergy and Critical Care Medicine and Director of the Adult Pulmonary Hypertension Program. The designation as a leading PH Care Center in the United States continues to be a major achievement made possible by the efforts of the clinical and research teams, especially during the last 2 years challenged by a global pandemic.
“The Pulmonary Hypertension Association’s Scientific Leadership Council, 28 global leaders in the field of pulmonary hypertension, have spearheaded the PHA-Accredited PH Care Centers (PHCC) initiative to establish a program for accreditation of centers with special expertise in pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), to raise the overall quality of care and outcomes in patients with this life-threatening disease.”
Roham Zamanian, MD, FCCP
Special Edition phaware® Podcast with Dr. Roham Zamanian
Our friends at phaware® shared a special edition podcast with Roham Zamanian, MD, FCCP, Associate Professor in the Division of Pulmonary, Allergy and Critical Care Medicine and Director of the Adult Pulmonary Hypertension Program, discussing the coronavirus (COVID-19) and gives specific advice for the PH Community.
Vinicio de Jesus Perez, MD and Roham Zamanian, MD, FCCP
Congratulations to Vinicio de Jesus Perez and Roham Zamanian for a High Impact COVID-19 Story
Roham Zamanian, MD, FCCP, Associate Professor in the Division of Pulmonary, Allergy and Critical Care Medicine and Director of the Adult Pulmonary Hypertension Program and Vinicio de Jesus Perez, MD, Associate Professor of Medicine in Pulmonary, Allergy, and Critical Care Medicine, along with other distinguished colleagues, published their fascinating case report in the American Journal of Respiratory and Critical Care Medicine detailing the outpatient management of a patient with concomitant idiopathic pulmonary arterial hypertension (iPAH) and COVID-19 disease using inhaled nitric oxide (iNO).
Kristina Kudelko, MD
Roham Zamanian, MD, FCCP
Roham Zamanian, MD, FCCP, Associate Professor in the Division of Pulmonary, Allergy and Critical Care Medicine and Director of the Adult Pulmonary Hypertension Program, along with leading pulmonary hypertension clinicians published an express manuscript about caring for PH patients with COVID-19.
Abstract: The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension (PH).The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary arterial hypertension (PAH), where PAH-specific treatments are used. It is important to balance the ongoing care andevaluation of PAH patients with “exposure risk” to COVID-19 for patients coming to clinic or the hospital. If there is a morbidity and mortality benefit from starting PAH therapies, for example in a patient with high-likelihood of PAH, then it remains important to complete the thorough evaluation. However, the COVID-19 outbreak may also represent a unique time when PH experts have to weigh the risks and benefits of the diagnostic work-up including potential exposure to COVID-19 versus initiatingtargeted PAH therapy in a select high-risk, highlikelihood World Symposium Pulmonary Hypertension (WSPH) Group 1 PAH patients.This document will highlight some of the issues facing providers, patients and the PAH community in real-time as the COVID-19 pandemic isevolving and is intended to share expected common clinical scenarios and best clinical practices to help the community at-large.